Home	Fast Track My Amedeo FAQ About	Flying Publisher
Fast Track	FPG #8: Alternative Treatments in Psychiatry FPG #7: Critical Care in Neurology	Free Medical Books

Lung Cancer

Free Subscription Articles published in Clin Cancer Res Retrieve available abstracts of 109 articles: HTML format Text format

Single Articles

January 2012
1. TAKAHASHI O , Komaki R, Smith PD, Jurgensmeier JM, et al
   Combined MEK and VEGFR Inhibition in orthotopic human lung cancer models results in enhanced inhibition of tumor angiogenesis, growth, and metastasis.
   Clin Cancer Res. 2012.
   PubMed     Text format     Related articles    Abstract available
   
   
   
   
2. WALTER K , Holcomb T, Januario T, Du P, et al
   DNA Methylation Profiling Defines Clinically Relevant Biological Subsets of Non-small Cell Lung Cancer.
   Clin Cancer Res. 2012.
   PubMed     Text format     Related articles    Abstract available
   
   
   
   
3. LEE Y , Shim HS, Park MS, Kim JH, et al
   High EGFR gene copy number and skin rash as predictive markers for EGFR tyrosine kinase inhibitors in patients with advanced squamous cell lung carcinoma.
   Clin Cancer Res. 2012.
   PubMed     Text format     Related articles    Abstract available
   
   
   
   
4. WAGNER KW , Ye Y, Lin J, Vaporciyan AA, et al
   Genetic Variations in Epigenetic Genes Are Predictors of Recurrence in Stage I or II Non-Small Cell Lung Cancer Patients.
   Clin Cancer Res. 2012;18:585-92.
   PubMed     Text format     Related articles    Abstract available
   
   
   
   
5. DOEBELE RC , Pilling AB, Aisner D, Kutateladze TG, et al
   Mechanisms of Resistance to Crizotinib in Patients with ALK Gene Rearranged Non-Small Cell Lung Cancer.
   Clin Cancer Res. 2012.
   PubMed     Text format     Related articles    Abstract available
   
   
   
   
6. PIETANZA MC , Kadota K, Huberman K, Sima CS, et al
   Phase II Trial of Temozolomide in Patients with Relapsed Sensitive or Refractory Small Cell Lung Cancer, with Assessment of Methyl-Guanine-DNA Methyltransferase as a Potential Biomarker.
   Clin Cancer Res. 2012.
   PubMed     Text format     Related articles    Abstract available
   
   
   
   
7. VALENCIA K , Ormazabal C, Zandueta C, Luis-Ravelo D, et al
   Inhibition of collagen receptor Discoidin Domain Receptor-1 (DDR1) Reduces Cell Survival, Homing and Colonization in Lung Cancer Bone Metastasis.
   Clin Cancer Res. 2012.
   PubMed     Text format     Related articles    Abstract available
   
   
   
   December 2011
8. PANDEY JP
   Prognostic Immune Markers in Non-Small Cell Lung Cancer--Letter.
   Clin Cancer Res. 2011.
   PubMed     Text format     Related articles   
   
   
   
   
9. SUZUKI K , Adusumilli PS
   Prognostic Immune Markers in Non-Small Cell Lung Cancer--Response.
   Clin Cancer Res. 2011.
   PubMed     Text format     Related articles   
   
   
   
   November 2011
10. AMBROSE LF , Freedman J, Buetow K, Friend S, et al
    Using patient-initiated study participation in the development of evidence for personalized cancer therapy.
    Clin Cancer Res. 2011;17:6651-7.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
11. BRUNSVIG PF , Kyte JA, Kersten C, Sundstrom S, et al
    Telomerase peptide vaccination in NSCLC: a phase II trial in stage III patients vaccinated after chemoradiotherapy and an 8-year update on a phase I/II trial.
    Clin Cancer Res. 2011;17:6847-57.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    October 2011
12. MASUDA K , Takano A, Oshita H, Akiyama H, et al
    Chondrolectin is a novel diagnostic biomarker and a therapeutic target for lung cancer.
    Clin Cancer Res. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
13. MASCAUX C , Wynes MW, Kato Y, Tran C, et al
    EGFR Protein Expression in Non-Small Cell Lung Cancer Predicts Response to an EGFR Tyrosine Kinase Inhibitor - A Novel Antibody for Immunohistochemistry or AQUA Technology.
    Clin Cancer Res. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    September 2011
14. KOSSENKOV AV , Vachani A, Chang C, Nichols C, et al
    Resection of non-small cell lung cancers reverses tumor-induced gene expression changes in the peripheral immune system.
    Clin Cancer Res. 2011;17:5867-77.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
15. TAN X , Qin W, Zhang L, Hang J, et al
    A Five-microRNA Signature for Squamous Cell Lung Carcinoma (SCC) Diagnosis and Hsa-miR-31 for SCC Prognosis.
    Clin Cancer Res. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    August 2011
16. CHAFT JE , Oxnard GR, Sima CS, Miller VA, et al
    Disease flare after tyrosine kinase inhibitor discontinuation in patients with EGFR-mutant lung cancer and acquired resistance to erlotinib or gefitinib.
    Clin Cancer Res. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
17. NISHINO R , Takano A, Oshita H, Ishikawa N, et al
    Identification of Epstein-Barr Virus-Induced Gene 3 as a Novel Serum and Tissue Biomarker and a Therapeutic Target for Lung Cancer.
    Clin Cancer Res. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
18. FATH M , Ahmad IM, Smith CJ, Spence JM, et al
    Enhancement of carboplatin-mediated lung cancer cell killing by simultaneous disruption of glutathione and thioredoxin metabolism.
    Clin Cancer Res. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
19. OXNARD GR , Janjigian YY, Arcila ME, Sima CS, et al
    Maintained sensitivity to EGFR tyrosine kinase inhibitors in EGFR-mutant lung cancer recurring after adjuvant erlotinib or gefitinib.
    Clin Cancer Res. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
20. ARAGAKI M , Takahashi K, Akiyama H, Tsuchiya E, et al
    Characterization of a Cleavage Stimulation Factor, 3' pre-RNA, Subunit 2, 64kDa (CSTF2) as a Therapeutic Target for Lung Cancer.
    Clin Cancer Res. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
21. SUNG WW , Wang YC, Cheng YW, Lee MC, et al
    A Polymorphic -844T/C in FasL Promoter Predicts Survival and Relapse in Non-Small Cell Lung Cancer.
    Clin Cancer Res. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    July 2011
22. OXNARD GR , Arcila ME, Chmielecki J, Ladanyi M, et al
    New Strategies in Overcoming Acquired Resistance to EGFR Tyrosine Kinase Inhibitors in Lung Cancer.
    Clin Cancer Res. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
23. TAN XL , Moyer AM, Fridley BL, Schaid D, et al
    Genetic variation predicting cisplatin cytotoxicity associated with overall survival in lung cancer patients receiving platinum-based chemotherapy.
    Clin Cancer Res. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
24. VAN DER VELDT AA , Lubberink M, Greuter HN, Comans EF, et al
    Absolute Quantification of [11C]docetaxel Kinetics in Lung Cancer Patients Using Positron Emission Tomography.
    Clin Cancer Res. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
25. XIE Y , Xiao G, Coombes K, Behrens C, et al
    Robust Gene Expression Signature from Formalin-Fixed Paraffin-Embedded Samples Predicts Prognosis of Non-Small-Cell Lung Cancer Patients.
    Clin Cancer Res. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
26. TASSINARI D , Lazzari-Agli L, Tombesi P, Sartori S, et al
    Gefitinib versus docetaxel for previously treated NSCLC--letter.
    Clin Cancer Res. 2011;17:4610.
    PubMed     Text format     Related articles   
    
    
    
    June 2011
27. GLUBB DM , Cerri E, Giese A, Zhang W, et al
    Novel functional germline variants in the vascular endothelial growth factor receptor 2 gene (KDR) and their effect on gene expression and microvessel density in lung cancer.
    Clin Cancer Res. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
28. PONZ-SARVISE M , Nguewa PA, Pajares MJ, Agorreta J, et al
    Inhibitor of differentiation-1 as a novel prognostic factor in NSCLC patients with adenocarcinoma histology and its potential contribution to therapy resistance.
    Clin Cancer Res. 2011;17:4155-66.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
29. YOON DH , Baek S, Choi CM, Lee DH, et al
    FDG-PET as a potential tool for selecting patients with advanced non-small cell lung cancer who may be spared maintenance therapy after first-line chemotherapy.
    Clin Cancer Res. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
30. SUZUKI K , Kachala SS, Kadota K, Shen R, et al
    Prognostic Immune Markers in Non-Small Cell Lung Cancer.
    Clin Cancer Res. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
31. LI Y , Sun Z, Cunningham JM, Aubry MC, et al
    Genetic variations in multiple drug action pathways and survival in advanced stage non-small cell lung cancer treated with chemotherapy.
    Clin Cancer Res. 2011;17:3830-40.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
32. ANDERSSON A , Srivastava MK, Harris-White M, Huang M, et al
    Role of CXCR3 Ligands in IL-7/IL-7R{alpha}-Fc-Mediated Antitumor Activity in Lung Cancer.
    Clin Cancer Res. 2011;17:3660-72.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
33. GILLIES SD , Lan Y, Hettmann T, Brunkhorst B, et al
    A low-toxicity IL-2-based immunocytokine retains antitumor activity despite its high degree of IL-2 receptor selectivity.
    Clin Cancer Res. 2011;17:3673-85.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
34. BROET P , Dalmasso C, Tan EH, Alifano M, et al
    Genomic profiles specific to patient ethnicity in lung adenocarcinoma.
    Clin Cancer Res. 2011;17:3542-50.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    May 2011
35. BEGUM S , Brait M, Dasgupta S, Ostrow KL, et al
    An epigenetic marker panel for detection of lung cancer using cell-free serum.
    Clin Cancer Res. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
36. YIN JY , Shen J, Dong Z, Huang Q, et al
    Effect of eIF3a on response of lung cancer patients to platinum-based chemotherapy by regulating DNA repair.
    Clin Cancer Res. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
37. RENGAN R , Maity A, Stevenson JP, Hahn SM, et al
    New Strategies in Non-small cell lung cancer: Improving outcomes in chemoradiotherapy for locally advanced disease.
    Clin Cancer Res. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
38. RIZVI NA , Rusch V, Pao W, Chaft JE, et al
    Molecular characteristics predict clinical outcomes: prospective trial correlating response to the EGFR tyrosine kinase inhibitor gefitinib with the presence of sensitizing mutations in the tyrosine binding domain of the EGFR gene.
    Clin Cancer Res. 2011;17:3500-6.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
39. TAKEUCHI K , Soda M, Togashi Y, Sugawara E, et al
    Pulmonary inflammatory myofibroblastic tumor expressing a novel fusion, PPFIBP1-ALK: reappraisal of anti-ALK immunohistochemistry as a tool for novel ALK fusion identification.
    Clin Cancer Res. 2011;17:3341-8.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
40. BHAN S , Negi SS, Shao C, Glazer CA, et al
    BORIS binding to the promoters of cancer testis antigens, MAGEA2, MAGEA3 and MAGEA4, is associated with their transcriptional activation in lung cancer.
    Clin Cancer Res. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
41. ZANDER T , Hofmann A, Staratschek-Jox A, Classen S, et al
    Blood-Based Gene Expression Signatures in Non-Small Cell Lung Cancer.
    Clin Cancer Res. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    April 2011
42. WU JY , Yu CJ, Chang YC, Yang JC, et al
    Effectiveness of tyrosine kinase inhibitors on uncommon epidermal growth factor receptor mutations of unknown clinical significance in non-small cell lung cancer.
    Clin Cancer Res. 2011.
    PubMed     Text format     Related articles   
    
    
    
    
43. SINGH PP , Joshi S, Russell PJ, Verma ND, et al
    Molecular chemotherapy and Chemotherapy: A new front against late stage hormone refractory prostate cancer.
    Clin Cancer Res. 2011.
    PubMed     Text format     Related articles   
    
    
    
    
44. LENG S , Bernauer AM, Hong C, Do KC, et al
    The A/G allele of rs16906252 predicts for MGMT methylation and is selectively silenced in premalignant lesions from smokers and in lung adenocarcinomas.
    Clin Cancer Res. 2011;17:2014-23.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
45. SAITO M , Schetter AJ, Mollerup S, Kohno T, et al
    The association of microRNA expression with prognosis and progression in early-stage, non-small cell lung adenocarcinoma: a retrospective analysis of three cohorts.
    Clin Cancer Res. 2011;17:1875-82.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    March 2011
46. ZANDI R , Selivanova G, Christensen CL, Gerds TA, et al
    PRIMA-1Met/APR-246 induces apoptosis and tumor growth delay in small cell lung cancer expressing mutant p53.
    Clin Cancer Res. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
47. TAKEZAWA K , Okamoto I, Nishio K, Janne P, et al
    Role of ERK-BIM and STAT3-survivin signaling pathways in ALK inhibitor-induced apoptosis in EML4-ALK-positive lung cancer.
    Clin Cancer Res. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
48. HAN JY , Lee SH, Yoo NJ, Hyung LS, et al
    A Randomized Phase II Study of Gefitinib Plus Simvastatin Versus Gefitinib Alone in Previously Treated Patients with Advanced Non-Small Cell Lung Cancer.
    Clin Cancer Res. 2011;17:1553-60.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
49. KADARA H , Behrens C, Yuan P, Solis L, et al
    A five-gene and corresponding protein signature for stage-I lung adenocarcinoma prognosis.
    Clin Cancer Res. 2011;17:1490-501.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
50. IWAKAWA R , Kohno T, Kato M, Shiraishi K, et al
    MYC amplification as a prognostic marker of early-stage lung adenocarcinoma identified by whole genome copy number analysis.
    Clin Cancer Res. 2011;17:1481-9.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
51. MILESHKIN L , Hicks RJ, Hughes BG, Mitchell P, et al
    Changes in FDG- and FLT-PET Imaging in Patients with Non-Small Cell Lung Cancer Treated with Erlotinib.
    Clin Cancer Res. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
52. JANNE PA , Boss DS, Camidge DR, Britten CD, et al
    Phase I dose-escalation study of the pan-HER inhibitor, PF299804, in patients with advanced malignant solid tumors.
    Clin Cancer Res. 2011;17:1131-9.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    February 2011
53. WU DW , Liu WS, Wang J, Chen CY, et al
    Reduced p21WAF1/CIP1 via Alteration of p53-DDX3 Pathway is associated with poor relapse free survival in Early-stage Human Papillomavirus-associated Lung cancer.
    Clin Cancer Res. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
54. SONG L , Xiong H, Li M, Liao WT, et al
    Sphingosine kinase-1 Enhances Resistance to Apoptosis through Activation of PI3K/Akt/NF-{kappa}B Pathway in Human Non-small Cell Lung Cancer.
    Clin Cancer Res. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
55. RUDIN CM , Poirier JT, Senzer NN, Stephenson J Jr, et al
    Phase I clinical study of Seneca Valley Virus (SVV-001), a replication-competent picornavirus, in advanced solid tumors with neuroendocrine features.
    Clin Cancer Res. 2011;17:888-95.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
56. CHEN G , Kim SH, King AN, Zhao L, et al
    CYP24A1 is an independent prognostic marker of survival in patients with lung adenocarcinoma.
    Clin Cancer Res. 2011;17:817-26.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
57. SHAW AT , Solomon B
    Targeting Anaplastic Lymphoma Kinase in Lung Cancer.
    Clin Cancer Res. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    January 2011
58. MCKINLEY ET , Bugaj JE, Zhao P, Guleryuz S, et al
    18FDG-PET predicts pharmacodynamic response to OSI-906, a dual IGF-1R/IR inhibitor, in preclinical mouse models of lung cancer.
    Clin Cancer Res. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
59. DIAMANDIS EP , Goodglick L, Planque C, Thornquist MD, et al
    Pentraxin-3 is a Novel Biomarker of Lung Carcinoma.
    Clin Cancer Res. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
60. TANG X , Kadara H, Behrens C, Liu D, et al
    Abnormalities of the TITF-1 lineage-specific oncogene in NSCLC: Implications in lung cancer pathogenesis and prognosis.
    Clin Cancer Res. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
61. ARCILA ME , Oxnard GR, Nafa K, Riely GJ, et al
    Rebiopsy of Lung Cancer Patients with Acquired Resistance to EGFR Inhibitors and Enhanced Detection of the T790M Mutation Using a Locked Nucleic Acid-Based Assay.
    Clin Cancer Res. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
62. HARADA T , Yatabe Y, Takeshita M, Koga T, et al
    Role and relevance of TrkB mutations and expression in non-small cell lung cancer.
    Clin Cancer Res. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
63. MITRA R , Lee J, Jo J, Milani M, et al
    Prediction of Postoperative Recurrence-Free Survival in Non-small Cell Lung Cancer by Using an Internationally Validated Gene Expression Model.
    Clin Cancer Res. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
64. DE RIENZO A , Dong L, Yeap BY, Jensen RV, et al
    Fine-needle aspiration biopsies for gene expression ratio-based diagnostic and prognostic tests in malignant pleural mesothelioma.
    Clin Cancer Res. 2011;17:310-6.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
65. TIE J , Lipton L, Desai J, Gibbs P, et al
    KRAS Mutation is Associated with Lung Metastasis in Patients with Curatively Resected Colorectal Cancer.
    Clin Cancer Res. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
66. ROSELL R , Molina MA, Costa C, Simonetti S, et al
    Pre-treatment EGFR T790M mutation and BRCA1 mRNA expression in erlotinib-treated advanced non-small-cell lung cancer patients with EGFR mutations.
    Clin Cancer Res. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
67. KELLY RJ , Rajan A, Force J, Keen C, et al
    Evaluation of KRAS mutations, angiogenic biomarkers and DCE-MRI in patients with advanced non-small cell lung cancer receiving sorafenib.
    Clin Cancer Res. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
68. TAN N , Malek M, Zha J, Kassees R, et al
    Navitoclax Enhances the Efficacy of Taxanes in Non-Small Cell Lung Cancer Models.
    Clin Cancer Res. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
69. DONEV IS , Wang W, Yamada T, Li Q, et al
    Transient PI3K Inhibition Induces Apoptosis and Overcomes HGF-mediated Resistance to EGFR-TKIs in EGFR Mutant Lung Cancer.
    Clin Cancer Res. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    December 2010
70. NEAL JW , Shaw AT
    One allele's loss is another's gain: Alterations of NKX2-8 in non-small cell lung cancer.
    Clin Cancer Res. 2010.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
71. RAMASAMY K , Nield L, Serkova NJ, Hasebroock KM, et al
    Silibinin Prevents Lung Tumorigenesis in Wild-type but not in iNOS-/- Mice: Potential of Real-time Micro-CT in Lung Cancer Chemoprevention Studies.
    Clin Cancer Res. 2010.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
72. HARRIS T , Pan Q, Sironi J, Lutz D, et al
    Both gene amplification and allelic loss occur at 14q13.3 in lung cancer.
    Clin Cancer Res. 2010.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
73. CHAPMAN CJ , Thorpe AJ, Murray A, Parsy-Kowalska C, et al
    Immuno-Biomarkers in Small Cell Lung Cancer: Potential Early Cancer Signals.
    Clin Cancer Res. 2010.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
74. OXNARD GR , Arcila ME, Sima C, Riely GJ, et al
    Acquired resistance to EGFR tyrosine kinase inhibitors in EGFR mutant lung cancer: Distinct natural history of patients with tumors harboring the T790M mutation.
    Clin Cancer Res. 2010.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
75. HERBST RS , Kurzrock R, Hong DS, Valdivieso M, et al
    A first-in-human study of conatumumab in adult patients with advanced solid tumors.
    Clin Cancer Res. 2010;16:5883-91.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    November 2010
76. HOFMAN V , Bonnetaud C, Ilie MI, Vielh P, et al
    Preoperative circulating tumor cell detection using the isolation by size of epithelial tumor cell method for patients with lung cancer is a new prognostic biomarker.
    Clin Cancer Res. 2010.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
77. JOHN T , Kohler D, Pintilie M, Yanagawa N, et al
    The Ability to Form Primary Tumor Xenografts is Predictive of Increased Risk of Disease Recurrence in Early Stage Non-small Cell Lung Cancer.
    Clin Cancer Res. 2010.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
78. SUDA K , Murakami I, Katayama T, Tomizawa K, et al
    Reciprocal and Complementary Role of MET Amplification and EGFR T790M Mutation in Acquired Resistance to Kinase Inhibitors in Lung Cancer.
    Clin Cancer Res. 2010.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
79. CAMIDGE DR , Kono SA, Flacco A, Tan AC, et al
    Optimizing the Detection of Lung Cancer Patients Harboring Anaplastic Lymphoma Kinase (ALK) Gene Rearrangements Potentially Suitable for ALK Inhibitor Treatment.
    Clin Cancer Res. 2010.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
80. CHMIELECKI J , Pao W
    Highly Active Antitumor Therapy (HAATT) for Epidermal Growth Factor Receptor-Mutant Lung Cancer.
    Clin Cancer Res. 2010.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
81. STABILE LP , Dacic S, Land SR, Lenzner DE, et al
    Combined analysis of estrogen receptor {beta}-1 and progesterone receptor expression identifies lung cancer patients with poor outcome.
    Clin Cancer Res. 2010.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
82. KAWAGUCHI T , Ando M, Kubo A, Takada M, et al
    Long exposure of environmental tobacco smoke associated with activating epidermal growth factor receptor mutations in never-smokers with non-small cell lung cancer.
    Clin Cancer Res. 2010.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
83. TARHINI AA , Kotsakis A, Gooding WE, Shuai Y, et al
    Phase II study of everolimus (RAD001) in previously treated small cell lung cancer.
    Clin Cancer Res. 2010.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    October 2010
84. HEON S , Yeap BY, Britt GJ, Costa DB, et al
    Development of Central Nervous System Metastases in Patients with Advanced Non-Small Cell Lung Cancer and Somatic EGFR Mutations Treated with Gefitinib or Erlotinib.
    Clin Cancer Res. 2010.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
85. WU HH , Wu JY, Cheng YW, Chen CY, et al
    cIAP2 Upregulated by E6 Oncoprotein via Epidermal Growth Factor Receptor/Phosphatidylinositol 3-Kinase/AKT Pathway Confers Resistance to Cisplatin in Human Papillomavirus 16/18-Infected Lung Cancer.
    Clin Cancer Res. 2010.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
86. SAKAIRI Y , Nakajima T, Yasufuku K, Ikebe D, et al
    EML4-ALK fusion gene assessment using metastatic lymph node samples obtained by endobronchial ultrasound-guided transbronchial needle aspiration.
    Clin Cancer Res. 2010;16:4938-45.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
87. HARIRI G , Yan H, Wang H, Han Z, et al
    Radiation-guided drug delivery to mouse models of lung cancer.
    Clin Cancer Res. 2010;16:4968-77.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
88. ZHU CQ , Strumpf D, Li CY, Li Q, et al
    Prognostic gene expression signature for squamous cell carcinoma of lung.
    Clin Cancer Res. 2010;16:5038-47.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
89. PATAER A , Raso MG, Correa AM, Behrens C, et al
    Prognostic significance of RNA-dependent protein kinase (PKR) on non-small cell lung cancer patients.
    Clin Cancer Res. 2010.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
90. HIRSCH FR , Wynes MW, Gandara DR, Bunn PA Jr, et al
    The Tissue Is the Issue: Personalized Medicine for Non-Small Cell Lung Cancer.
    Clin Cancer Res. 2010.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
91. MAITY A , Koumenis C
    Location, location, location-makes all the difference for hypoxia in lung tumors.
    Clin Cancer Res. 2010;16:4685-7.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
92. WILKERSON MD , Yin X, Hoadley KA, Liu Y, et al
    Lung squamous cell carcinoma mRNA expression subtypes are reproducible, clinically important, and correspond to normal cell types.
    Clin Cancer Res. 2010;16:4864-75.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    September 2010
93. GRAVES EE , Vilalta M, Cecic IK, Erler JT, et al
    Hypoxia in Models of Lung Cancer: Implications for Targeted Therapeutics.
    Clin Cancer Res. 2010.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
94. ALIFANO M , Souaze F, Dupouy S, Camilleri-Broet S, et al
    Neurotensin receptor 1 determines the outcome of non-small cell lung cancer.
    Clin Cancer Res. 2010;16:4401-10.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
95. MARTINELLI E , Troiani T, Morgillo F, Rodolico G, et al
    Synergistic Antitumor Activity of Sorafenib in Combination with Epidermal Growth Factor Receptor Inhibitors in Colorectal and Lung Cancer Cells.
    Clin Cancer Res. 2010.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
96. JIANG SS , Fang WT, Hou YH, Huang SF, et al
    Upregulation of SOX9 in lung adenocarcinoma and its involvement in the regulation of cell growth and tumorigenicity.
    Clin Cancer Res. 2010;16:4363-73.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    August 2010
97. XU H , Krystal GW
    Actinomycin D Decreases Mcl-1 Expression and Acts Synergistically with ABT-737 against Small Cell Lung Cancer Cell Lines.
    Clin Cancer Res. 2010.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
98. EZPONDA T , Pajares MJ, Agorreta J, Echeveste JI, et al
    The Oncoprotein SF2/ASF Promotes Non-Small Cell Lung Cancer Survival by Enhancing Survivin Expression.
    Clin Cancer Res. 2010.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
99. KATZ RL , He W, Khanna A, Fernandez RL, et al
    Genetically Abnormal Circulating Cells in Lung Cancer Patients: An Antigen-Independent Fluorescence In situ Hybridization-Based Case-Control Study.
    Clin Cancer Res. 2010;16:3976-87.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
100. ARNDT CA , Koshkina NV, Inwards CY, Hawkins DS, et al
     Inhaled granulocyte-macrophage colony stimulating factor for first pulmonary recurrence of osteosarcoma: effects on disease-free survival and immunomodulation. a report from the Children's Oncology Group.
     Clin Cancer Res. 2010;16:4024-30.
     PubMed     Text format     Related articles    Abstract available
     
     
     
     
101. PISANO C , Vesci L, Milazzo FM, Guglielmi MB, et al
     Metabolic approach to the enhancement of antitumor effect of chemotherapy: a key role of acetyl-L-carnitine.
     Clin Cancer Res. 2010;16:3944-53.
     PubMed     Text format     Related articles    Abstract available
     
     
     
     July 2010
102. GUALBERTO A , Dolled-Filhart M, Gustavson M, Christiansen JJ, et al
     Molecular Analysis of Non-Small Cell Lung Cancer (NSCLC) Identifies Subsets with Different Sensitivity to Insulin like Growth Factor I Receptor (IGF-IR) Inhibition.
     Clin Cancer Res. 2010.
     PubMed     Text format     Related articles    Abstract available
     
     
     
     
103. ZHANG W , Zhu XD, Sun HC, Xiong YQ, et al
     Depletion of tumor-associated macrophages enhances the effect of sorafenib in metastatic liver cancer models by antimetastatic and antiangiogenic effects.
     Clin Cancer Res. 2010;16:3420-30.
     PubMed     Text format     Related articles    Abstract available
     
     
     
     June 2010
104. AMORNSIRIPANITCH N , Hong S, Campa MJ, Frank MM, et al
     Complement factor H autoantibodies are associated with early stage NSCLC.
     Clin Cancer Res. 2010;16:3226-31.
     PubMed     Text format     Related articles    Abstract available
     
     
     
     
105. LANTUEJOUL S , Raynaud C, Salameire D, Gazzeri S, et al
     Telomere maintenance and DNA damage responses during lung carcinogenesis.
     Clin Cancer Res. 2010;16:2979-88.
     PubMed     Text format     Related articles    Abstract available
     
     
     
     May 2010
106. DICKGREBER NJ , Sorensen JB, Paz-Ares LG, Schytte TK, et al
     Pemetrexed safety and pharmacokinetics in patients with third-space fluid.
     Clin Cancer Res. 2010;16:2872-80.
     PubMed     Text format     Related articles    Abstract available
     
     
     
     
107. WANG S , Ren W, Liu J, Lahat G, et al
     TRAIL and doxorubicin combination induces proapoptotic and antiangiogenic effects in soft tissue sarcoma in vivo.
     Clin Cancer Res. 2010;16:2591-604.
     PubMed     Text format     Related articles    Abstract available
     
     
     
     April 2010
108. PICARDA G , Lamoureux F, Geffroy L, Delepine P, et al
     Preclinical evidence that use of TRAIL in Ewing's sarcoma and osteosarcoma therapy inhibits tumor growth, prevents osteolysis, and increases animal survival.
     Clin Cancer Res. 2010;16:2363-74.
     PubMed     Text format     Related articles    Abstract available
     
     
     
     
109. USUDA J , Ichinose S, Ishizumi T, Hayashi H, et al
     Outcome of photodynamic therapy using NPe6 for bronchogenic carcinomas in central airways >1.0 cm in diameter.
     Clin Cancer Res. 2010;16:2198-204.
     PubMed     Text format     Related articles    Abstract available
     
     
     

Thank you for your interest in scientific medicine.

Amedeo is a Flying Publisher website.    Design: